Persistent induction of goblet cell differentiation in the airways: Therapeutic approaches

Andrew T. Reid, Punnam Chander Veerati, Reinoud Gosens, Nathan W. Bartlett, Peter A. Wark, Chris L. Grainge, Stephen M. Stick, Anthony Kicic, Fatemeh Moheimani, Philip M. Hansbro, Darryl A. Knight

Research output: Contribution to journalReview article

12 Citations (Scopus)

Abstract

Dysregulated induction of goblet cell differentiation results in excessive production and retention of mucus and is a common feature of several chronic airways diseases. To date, therapeutic strategies to reduce mucus accumulation have focused primarily on altering the properties of the mucus itself, or have aimed to limit the production of mucus-stimulating cytokines. Here we review the current knowledge of key molecular pathways that are dysregulated during persistent goblet cell differentiation and highlights both pre-existing and novel therapeutic strategies to combat this pathology.

Original languageEnglish
Pages (from-to)155-169
JournalPharmacology and Therapeutics
DOIs
Publication statusPublished - 1 Jan 2018

Fingerprint Dive into the research topics of 'Persistent induction of goblet cell differentiation in the airways: Therapeutic approaches'. Together they form a unique fingerprint.

  • Cite this

    Reid, A. T., Veerati, P. C., Gosens, R., Bartlett, N. W., Wark, P. A., Grainge, C. L., Stick, S. M., Kicic, A., Moheimani, F., Hansbro, P. M., & Knight, D. A. (2018). Persistent induction of goblet cell differentiation in the airways: Therapeutic approaches. Pharmacology and Therapeutics, 155-169. https://doi.org/10.1016/j.pharmthera.2017.12.009